摘要
回顾性分析低剂量地西他滨皮下注射联合三氧化二砷诱导治疗11例中高危骨髓增生异常综合征(MDS)的安全性及疗效。所有患者均顺利完成治疗;11例MDS中,完全缓解3例,骨髓缓解伴血象不完全恢复(CRi)+血液学进步(HI)6例,疾病稳定1例,疾病进展1例。其中1例CRi+HI后行异基因造血干细胞移植。中位随访时间为413(90-1275)d,9例存活至今。研究结果提示,对于中高危MDS,低剂量地西他滨皮下注射联合三氧化二砷治疗安全、有效。
To retrospectively analyze the safety and efficacy of low dose subcutaneous decitabine combined with arsenic trioxide in patients with intermediate or high-risk myelodysplastic syndrome(MDS).Three of the total 11 MDS patients achieved complete remission(CR)and 6 achieved hematological improvement(HI),1 stable disease(SD),and 1 progressive disease(PD).One patient was treated with allogeneic hematopoietic stem cell transplantation(allo-HSCT).The median follow-up time was 413(90-1275)d.Nine patients were still alive.Low dose subcutaneous decitabine combined with arsenic trioxide can be an alternative regimen for intermediate or high-risk MDS patients.
作者
艾昊
魏旭东
尹青松
米瑞华
陈琳
王倩
宋永平
Ai Hao;Wei Xudong;Yin Qingsong;Mi Ruihua;Chen Lin;Wang Qian;Song Yongping(Department of Hematology,the Affiliated Cancer Hospital of Zhengzhou University,Zhengzhou 450008,China)
出处
《中华内科杂志》
CAS
CSCD
北大核心
2019年第12期908-910,共3页
Chinese Journal of Internal Medicine
基金
河南省科技攻关计划项目(182102310381)
河南省医学科技攻关计划省部共建项目(201701027)。
